Cartesian Therapeutics, Inc. — Director's Dealing 2023

Jan 4, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2023-01-02

Reporting Person: Kishimoto Takashi Kei (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-02	Common Stock	A	100000	—	Acquired	374100	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-02	Employee Stock Option (right to buy)	$1.13	A	475000	Acquired	2033-01-01	Common Stock (475000.0)	Direct

Footnotes

F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2024. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2027.

F2: Includes 5,747 shares of common stock purchased under the Issuer's Employee Stock Purchase Program during the contribution period between September 1, 2021 and February 28, 2022.

F3: This option vests as to 25% on January 2, 2024. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter.